Leap Therapeutics, Inc.

NasdaqCM:LPTX Voorraadrapport

Marktkapitalisatie: US$98.0m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Leap Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Leap Therapeutics' is Doug Onsi, benoemd in Jan2011, heeft een ambtstermijn van 13.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.53M, bestaande uit 43.6% salaris en 56.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde $ 189.27K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 7.8 jaar.

Belangrijke informatie

Doug Onsi

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris43.6%
Dienstverband CEO13.8yrs
Eigendom CEO0.2%
Management gemiddelde ambtstermijn4.5yrs
Gemiddelde ambtstermijn bestuur7.8yrs

Recente managementupdates

Recent updates

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Mar 13
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?

Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Nov 22
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?

Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05

Aug 12

Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers

Jul 12

Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022

Jun 27

Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

May 01
Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation

Leap Therapeutics: Waiting For One More Leap

Feb 18

We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Jan 04
We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely

Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?

Nov 29

Leap Therapeutics: All On The Line

Oct 13

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Sep 15
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Jun 01
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?

Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Mar 03
Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth

Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Jan 27
Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?

Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Dec 23
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year

Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Nov 18
Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)

Analyse CEO-vergoeding

Hoe is Doug Onsi's beloning veranderd ten opzichte van Leap Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$60m

Mar 31 2024n/an/a

-US$53m

Dec 31 2023US$2mUS$669k

-US$81m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$86m

Dec 31 2022US$2mUS$637k

-US$55m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$42m

Dec 31 2021US$2mUS$596k

-US$41m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$2mUS$513k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$40m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$817kUS$400k

-US$33m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$22m

Mar 31 2019n/an/a

-US$21m

Dec 31 2018US$682kUS$400k

-US$23m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$397k

-US$30m

Compensatie versus markt: De totale vergoeding ($USD 1.53M ) Doug } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Doug is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Doug Onsi (55 yo)

13.8yrs

Tenure

US$1,534,507

Compensatie

Mr. Douglas E. Onsi, also known as Doug, J.D., serves as Director at Leap Therapeutics, Inc. since March 18, 2020. He serves as Managing Director of HCV Management VIII, LLC (formerly known as HealthCare V...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Douglas Onsi
CFO, General Counsel13.8yrsUS$1.53m0.19%
$ 188.5k
Augustine Lawlor
Chief Operating Officer8.8yrsUS$1.00m0.013%
$ 13.0k
Cynthia Sirard
Chief Medical Officer4.5yrsUS$999.40k0.013%
$ 12.8k
Jason Baum
Chief Scientific Officer1.5yrsgeen gegevensgeen gegevens
Mark O'Mahony
Chief Manufacturing Officer4.5yrsgeen gegevens0.013%
$ 12.8k
Christine Granfield
VP and Head of Regulatory Affairs & Quality4.2yrsgeen gegevensgeen gegevens

4.5yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LPTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Douglas Onsi
CFO, General Counsel4.6yrsUS$1.53m0.19%
$ 188.5k
Christopher Mirabelli
Chairman13.8yrsUS$744.18k0.013%
$ 13.0k
James Cavanaugh
Independent Director8.8yrsUS$126.62k0%
$ 0
Thomas Dietz
Lead Independent Director8.8yrsUS$188.86k0%
$ 0
Nissim Mashiach
Independent Director7.8yrsUS$118.24k0%
$ 0
Joseph Loscalzo
Independent Director8.8yrsUS$112.12k0%
$ 0
William Li
Independent Director7.8yrsUS$121.62k0%
$ 0
Carl Nathan
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Richard Schilsky
Independent Director2.1yrsUS$112.12k0%
$ 0
Richard Brian Gaynor
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens
David Tuveson
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Andrew Nixon
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens

7.8yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LPTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).